-
公开(公告)号：SK94198A3
公开(公告)日：1999-03-10
申请号：SK94198
申请日：1997-01-10
Applicant: BASF AG
Inventor： TREIBER HANS-JORG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , C07D243/08 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
162.发明专利
公开(公告)号：CA2301297A1
公开(公告)日：1999-02-25
申请号：CA2301297
申请日：1998-08-14
Applicant: BASF AG
Inventor： SCHAFER BERND , STARCK DOROTHEA , BLANK STEFAN , THYES MARCO , TREIBER HANS-JORG , KOSER STEFAN , HOGER THOMAS
IPC: C07D239/56 , A61K20060101 , A61K31/395 , A61K31/497 , A61K31/505 , A61K31/506 , A61P1/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/24 , A61P43/00 , C07D20060101 , C07D239/42 , C07D239/46 , C07D295/125 , C07D403/00 , C07D403/12 , C07D403/14
Abstract: The invention relates to the fumaric acid salt from 2-{3-4-(2-T-butyl-6-trifluoromethylpyridin-4-yl) piperazin-1-yl! propylmercapto} pyrimidin-4-ol and to pharmaceutical agents containing said salt. The salt can be used for treating diseases which respond to dopamine-D3 ligands. It is very stable at a low pH and is therefore especially suitable for oral administration.
-
公开(公告)号：DE19734444A1
公开(公告)日：1999-02-11
申请号：DE19734444
申请日：1997-08-08
Applicant: BASF AG
Inventor： STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JUERGEN , GARCIA-LADONA FRANCISCO-JAVI , EMLING FRANZ
IPC: A61K31/435 , A61P25/24 , C07D495/14 , A61K31/505
Abstract: 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-Dpyrimidine derivatives of formula (I), in which the substituents have the meaning given in the description, their preparation and their use as medicaments.
-
164.发明专利
公开(公告)号：PL327692A1
公开(公告)日：1998-12-21
申请号：PL32769297
申请日：1997-01-10
Applicant: BASF AG
Inventor： TREIBER HANS-JOERG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHEDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , C07D243/08 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：TR9801302T2
公开(公告)日：1998-11-23
申请号：TR9801302
申请日：1997-01-10
Applicant: BASF AG
Inventor： TREIBER HANS-JOERG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: C07D243/08 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
CPC classification number: C07D403/04 , C07D403/12 , C07D403/14 , C07D417/14
-
Patent Agency Ranking
公开(公告)号：NO983187A
公开(公告)日：1998-09-09
申请号：NO983187
申请日：1998-07-10
Applicant: BASF AG
Inventor： TREIBER HANS-JOERG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHEDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D243/08 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D239/28
CPC classification number: C07D403/04 , C07D403/12 , C07D403/14 , C07D417/14
-
公开(公告)号：ZA97209B
公开(公告)日：1998-07-10
申请号：ZA97209
申请日：1997-01-10
Applicant: BASF AG
Inventor： BLANK STEFAN , TREIBER HANS-JOERG , STARCK DOROTHEA , UNGER LILIANE , WICKE KARSTEN , TESCHEDORF HANS-JUERGEN
IPC: A61K31/00 , A61K31/40 , A61K31/4025 , C07D243/08 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D , A61K
Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
公开(公告)号：HRP970021A2
公开(公告)日：1998-04-30
申请号：HRP970021
申请日：1997-01-10
Applicant: BASF AG
Inventor： TREIBER HANS-JOERG , BLANK STEFAN , STARCK DOROTHEA , UNGER LILIANE , TESCHEDORF HANS-JUERGEN , WICKE KARSTEN
IPC: C07D243/08 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/41 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61K31/4439 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P25/18 , A61P43/00 , C07D213/73 , C07D223/04 , C07D245/02 , C07D401/04 , C07D401/14 , C07D403/02 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula:where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.
-
169.发明专利
公开(公告)号：CA2368823C
公开(公告)日：2008-10-21
申请号：CA2368823
申请日：2000-04-28
Applicant: BASF AG
Inventor： GROSS GERHARD , STARCK DOROTHEA , TREIBER HANS-JORG , MUHLBAUER BERND
IPC: A61K31/506 , C07D241/04 , A61K31/00 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5513 , A61K45/00 , A61P1/00 , A61P13/12 , C07D401/12 , C07D403/12
Abstract: The invention relates to the use of dopamine D3 receptor ligands for producing medicaments for treating kidney disorders.
-
公开(公告)号：BG65086B1
公开(公告)日：2007-02-28
申请号：BG10578401
申请日：2001-08-03
Applicant: BASF AG
Inventor： STARCK DOROTHEA , TREIBER HANS-JOERG , UNGER LILIANE , NEUMANN-SCHULZ BARBARA , BLUMBACH KAI , SCHOEBEL DIETMAR
IPC: A61K31/19 , C07D249/14 , A61K31/41 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/436 , A61K31/4439 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/55 , A61P3/04 , A61P9/00 , A61P9/10 , A61P13/12 , A61P15/10 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P25/36 , A61P43/00 , C07D249/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D491/04 , C07D491/052
Abstract: The invention relates to triazole compounds of formula in which R1, R2, A and B have the meanings given in the description. The compounds provided for in the invention have a high affinity for the dopamine-D3-receptor and are therefore suitable for the treatment of diseases which respond to the influence of dopamine-D3-receptor ligands.
-
-
-
-
-
-
-
-
-
Search Results
216
records
(took 0.024 seconds)
